Board Appointment
Oxford BioDynamics Plc announced the immediate appointment of Richard Compton, Chief Executive Officer, to the Board as an Executive Director, following his prior CEO appointment and completion of regulatory due diligence. Mr. Compton holds 300,000,000 ordinary shares, representing 2.2% of the Company's ordinary share capital. He currently holds one directorship with Compton Advisory Ltd and has no previous directorships in the last five years.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford, UK - 27 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, today announces the appointment of Richard Compton, Chief Executive Officer, to the Board as an Executive Director with immediate effect. The appointment follows the Company's announcement of 30 June 2026 regarding Mr Compton's appointment as Chief Executive Officer and the completion of regulatory due diligence by the Company's Nomad.
Iain Ross, Non-Executive Chairman of Oxford BioDynamics, said:
"I am delighted to welcome Richard to the Board of OBD. In the short time he has been with the Company as CEO he has proven he has the qualities and experience to lead the team to commercial success. With the support of the shareholders I believe he will be able to realise the success for which we have all been striving."
The following disclosures are provided in respect of Richard Alan Compton, aged 56, pursuant to Schedule 2(g) of the AIM Rules for Companies.
Mr Compton holds 300,000,000 ordinary shares in the capital of the Company, representing 2.2% of the Company's ordinary share capital.
| Current Directorships / Partnerships | Previous Directorships / Partnerships (Last 5 years) |
| Compton Advisory Ltd (Company No. 16851684) | None. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.